Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

J.L. Vos, J.B.W. Elbers, O. Krijgsman, J.J.H. Traets, X.H. Qiao, A.M. Van der Leun, Y. Lubeck, I.M. Seignette, L.A. Smit, S.M. Willems, M.W.M. Van den Brekel, R. Dirven, M.B. Karakullukcu, L. Karssemakers, W.M.C. Klop, P.J.F.M. Lohuis, W.H. Schreuder, L.E. Smeele, L.A. Van der Velden, B. TanS. Onderwater, B. Jasperse, W.V. Vogel, A. Al-Mamgani, A. Keijser, V. Van der Noort, A. Broeks, E. Hooijberg, D.S. Peeper, T.N. Schumacher, C.U. Blank, J.P. De Boer, J.B.A.G. Haanen, C.L. Zuur*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number7348
Number of pages13
JournalNature Communications
Volume12
Issue number1
DOIs
Publication statusPublished - 22 Dec 2021

Keywords

  • SALVAGE SURGERY
  • OPEN-LABEL
  • RECURRENT
  • CHEMOTHERAPY
  • MUTAGENESIS
  • APOBEC
  • CANCER
  • TREMELIMUMAB
  • RADIOTHERAPY
  • DURVALUMAB

Cite this